Literature DB >> 7505269

5-Azacytidine (NSC 102816) in refractory germ cell tumors. A phase II trial of the Eastern Cooperative Oncology Group.

B J Roth1, P Elson, G W Sledge, L H Einhorn, D L Trump.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1993        PMID： 7505269     DOI： 10.1007/bf00874155

Source DB:  PubMed          Journal:  Invest New Drugs        ISSN： 0167-6997            Impact factor:   3.850


× No keyword cloud information.
  5 in total

1.  The inhibition of DNA(cytosine-5)methylases by 5-azacytidine. The effect of azacytosine-containing DNA.

Authors:  S Friedman
Journal:  Mol Pharmacol       Date:  1981-03       Impact factor: 4.436

2.  Variations in DNA methylation during mouse cell differentiation in vivo and in vitro.

Authors:  A Razin; C Webb; M Szyf; J Yisraeli; A Rosenthal; T Naveh-Many; N Sciaky-Gallili; H Cedar
Journal:  Proc Natl Acad Sci U S A       Date:  1984-04       Impact factor: 11.205

3.  Cellular differentiation, cytidine analogs and DNA methylation.

Authors:  P A Jones; S M Taylor
Journal:  Cell       Date:  1980-05       Impact factor: 41.582

4.  Phase II study of 5-azacytidine in solid tumors.

Authors:  J M Quagliana; R M O'Bryan; L Baker; J Gottlieb; F S Morrison; H J Eyre; W G Tucker; J Costanzi
Journal:  Cancer Treat Rep       Date:  1977 Jan-Feb

5.  5-Azacytidine is able to induce the conversion of teratocarcinoma-derived mesenchymal cells into epithelia cells.

Authors:  M Darmon; J F Nicolas; D Lamblin
Journal:  EMBO J       Date:  1984-05       Impact factor: 11.598
  5 in total
  6 in total

Review 1.  Platinum-refractory germ cell tumors: an update on current treatment options and developments.

Authors:  Christoph Oing; Winfried H Alsdorf; Gunhild von Amsberg; Karin Oechsle; Carsten Bokemeyer
Journal:  World J Urol       Date:  2016-07-23       Impact factor: 4.226

Review 2.  Emerging Therapeutic Targets for Male Germ Cell Tumors.

Authors:  Christian Daniel Fankhauser; Friedemann Honecker; Jörg Beyer; Peter Karl Bode
Journal:  Curr Oncol Rep       Date:  2015-12       Impact factor: 5.075

3.  Refractory testicular germ cell tumors are highly sensitive to the second generation DNA methylation inhibitor guadecitabine.

Authors:  Costantine Albany; Mary P Hever-Jardine; Katherine M von Herrmann; Christina Y Yim; Janice Tam; Joshua M Warzecha; Leah Shin; Sarah E Bock; Brian S Curran; Aneeq S Chaudhry; Fred Kim; George E Sandusky; Pietro Taverna; Sarah J Freemantle; Brock C Christensen; Lawrence H Einhorn; Michael J Spinella
Journal:  Oncotarget       Date:  2017-01-10

Review 4.  Targeting DNA Methyltranferases in Urological Tumors.

Authors:  Ângela Marques-Magalhães; Inês Graça; Rui Henrique; Carmen Jerónimo
Journal:  Front Pharmacol       Date:  2018-04-13       Impact factor: 5.810

5.  Targeting Germ Cell Tumors with the Newly Synthesized Flavanone-Derived Compound MLo1302 Efficiently Reduces Tumor Cell Viability and Induces Apoptosis and Cell Cycle Arrest.

Authors:  João Lobo; Ana Rita Cardoso; Vera Miranda-Gonçalves; Leendert H J Looijenga; Marie Lopez; Paola B Arimondo; Rui Henrique; Carmen Jerónimo
Journal:  Pharmaceutics       Date:  2021-01-07       Impact factor: 6.321

Review 6.  Epigenetic alterations as therapeutic targets in Testicular Germ Cell Tumours : current and future application of 'epidrugs'.

Authors:  Ana Rita Cardoso; João Lobo; Vera Miranda-Gonçalves; Rui Henrique; Carmen Jerónimo
Journal:  Epigenetics       Date:  2020-08-12       Impact factor: 4.528
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.